BCR and hematologic disorder: Recently, CD19 chimeric antigen receptor T-cell therapy (CAR-T) therapy, and Bi-specific T-cell engager (BiTE) therapies have shown promise in treating hematological malignancies that result from BCR fusion protein driven cancers [81–83].